| 1 Anghel SI, Wahli W. Fat poetry:a kingdom for PPAR gamma[J]. Cell Res, 2007, 17:486-511.2 Li J, Li JJ, He JG, et al. Atorvastatin decreases C-reactive protein induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappa B pathway[J]. Cardiovasc Ther, 2010, 28:8-14. 3 Jackson SM, Parhami F, Xi XP, et al. Peroxisome proliferators-activated receptor activators target human endothelial cell to inhibit leukocyte-endothelial cell interaction[J]. Arerioscler Thromb Vasc Biol, 1999, 19:2094-2104.4 Neve BP, Fruchart JC, Staels B. Role of the peroxisome proliferators-activated receptors (PPAR) in atherosclerosis[J]. Biochem Pharmacol, 2000, 60:1245-1250.5 Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation[J]. Nature, 1998, 391:79-82.6 Kintscher U, Goetze S, Wakino S, et al. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes[J]. Eur J Pharmacol, 2000, 401:259-270.7 Babaev VR, Yancey PG, Ryzhov SV, et al. Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice[J]. Arterioscler Thromb Vasc Bio, 2005, 25:1647-1653.8 Pasceri V, Wu HD, Willerson JT, et al. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators[J]. Circulation, 2000, 101:235-238.9 Ozasa H, Ayaori M, Iizuka M, et al. Pioglitazone enhances cholesterol efflux from macrophages by increasing ABCA1/ABCG1 expressions via PPARgamma/LXRalpha pathway:findings from in vitro and ex vivo studies[J]. Atherosclerosis, 2011, 219:141-150.10 Hamblin M, Chang L, Zhang H, et al. Vascular smooth muscle cell peroxisome proliferator-activated receptor-gamma mediates pioglitazone-reduced vascular lesion formation[J]. Arterioscler Thromb Vasc Biol, 2011, 31:352-359.11 Pelham CJ, Keen HL, Lentz SR, et al. Dominant negative PPARγ promotes atherosclerosis, vascular dysfunction, and hypertension through distinct effects in endothelium and vascular muscle[J]. Am J Physiol Regul Integr Comp Physiol, 2013, 304:R690-R701.12 Ding M, Carrão AC, Wagner RJ, et al. Vascular smooth muscle cell-derived adiponectin:a paracrine regulator of contractile phenotype[J]. J Mol Cell Cardiol, 2012, 52:474-484.13 Sasaki M, Jordan P, Welbourne T, et al. Troglitazone, a PPAR-gamma activator prevents endothelial cell adhesion molecule expression and lymphocyte adhesion mediated by TNF-alpha[J]. BMC Physiol,2005, 5:3.14 罗玉梅, 万新红, 姜德谦, 等. 过氧化物酶增殖物激活受体-γ调节体外诱导培养的人巨噬细胞表达基质金属蛋白酶-9及其抑制物-1的作用及机制[J]. 中华心血管病杂志, 2009, 37:739-745.15 Yuan X, Liu N. Pioglitazone suppresses advanced glycation end product-induced expression of plasminogen activator inhibitor-1 in vascular smooth muscle cells[J]. J Genet Genomics, 2011, 38:193-200.16 Giaginis C, Tsourouflis G, Theocharis S. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands:novel pharmacological agents in the treatment of ischemia reperfusion injury[J]. Curr Mol Med, 2008, 8:562-579.17 Kodera Y, Takeyama K, Murayama A, et al. Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators[J]. J Biol Chem, 2000, 275:33201-33204.18 Nakajima A, Wada K, Miki H, et al. Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury[J]. Gastroenterology, 2001, 120:460-469.19 Wada K, Nakajima A, Takahashi H, et al. Protective effect of endogenous PPARgamma against acute gastric mucosal lesions associated with ischemia-reperfusion[J]. Am J Physiol Gastrointest Liver Physiol, 2004, 287:G452-G458.20 Zingarelli B, Hake PW, Mangeshkar P, et al. Diverse cardioprotective signaling mechanisms of peroxisome proliferator-activated receptor-gamma ligands, 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone, in reperfusion injury:role of nuclear factor-kappaB, heat shock factor 1, and Akt[J]. Shock, 2007, 28:554-563.21 Morrison A, Yan X, Tong C, et al. Acute rosiglitazone treatment is cardioprotective against ischemia-reperfusion injury by modulating AMPK, Akt, and JNK signaling in nondiabetic mice[J]. Am J Physiol Heart Circ Physiol, 2011, 301:H895-H902.22 Xu Y, Lu L, Greyson C, et al. Deleterious effects of acute treatment with a peroxisome proliferator–activated receptor-γ activator in myocardial ischemia and reperfusion in pigs[J]. Diabetes, 2003, 52:1187.23 Campia U, Matuskey LA, Panza JA. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors[J]. Circulation, 2006, 113:867-875.24 Danton GH, Dietrich WD. Inflammatory mechanisms after ischemia and stroke[J]. J Neuropathol Exp Neurol, 2003, 62:127-136.25 Zhao Y, Patzer A, Herdegen T, et al. Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats[J]. FASEB J, 2006, 20:1162-1175.26 Liu JL, Jin JW, Pei SJ, et al. Flurbiprofen axetil promotes neuroprotection by activation of cerebral peroxisome proliferator-activated receptor gamma after focal cerebral ischemia in rats[J]. Chin Med J (Engl), 2012, 125:3719-3724.27 Palomares SM, Sweet JG, Cipolla MJ. Acute rosiglitazone treatment during reperfusion after hyperglycemic stroke is neuroprotective not vascular protective[J]. Transl Stroke Res, 2012, 3:390-396. |
